Palette Life Sciences is a fully-integrated medical device company focused on providing a wide range of products and services that improve the quality of life for patients. Led by experienced healthcare executives, the initial company strategy is to transform applications of existing technologies to bring forward novel solutions for underserved conditions. Our portfolio of products focuses on treating conditions in urology/urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures.
We are a passionate team of individuals who enjoy the thrill of building a company whose culture is one of curiosity, compassion and drive. Looking for like-minded staff that has a complementary experience to add to the team. Our superior benefits package is proof positive that we care about our people.
Deflux® - the only FDA-approved injectable treatment of vesicoureteral reflux (VUR), a malformation of the urinary bladder that affects 1% of children worldwide. VUR can cause severe infections of the urinary tract and lead to irreversible kidney damage.
Solesta® - the only FDA-approved injectable treatment for fecal incontinence, which is also cleared for commercialization in Europe. Fecal incontinence is a debilitating health problem afflicting about 2% of people worldwide with four times more prevalent in women than men.
Barrigel®* - a biodegradable injectable treatment for protection of the rectal wall when treating prostate cancer with radiation. The product is approved in Europe and will be further developed for future market introduction in the US.
Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California and Dallas, Texas. Learn more at palettelifesciences.com and pharmanest.se.
Deflux®, Solesta®, Barrigel®, Restylane®, and NASHA™ are registered trademarks.
*In the US, this product is considered investigational and not available for commercial sale in the US.
We are a passionate team of individuals who enjoy the thrill of building a company whose culture is one of curiosity, compassion and drive. Looking for like-minded staff that has a complementary experience to add to the team. Our superior benefits package is proof positive that we care about our people.
Deflux® - the only FDA-approved injectable treatment of vesicoureteral reflux (VUR), a malformation of the urinary bladder that affects 1% of children worldwide. VUR can cause severe infections of the urinary tract and lead to irreversible kidney damage.
Solesta® - the only FDA-approved injectable treatment for fecal incontinence, which is also cleared for commercialization in Europe. Fecal incontinence is a debilitating health problem afflicting about 2% of people worldwide with four times more prevalent in women than men.
Barrigel®* - a biodegradable injectable treatment for protection of the rectal wall when treating prostate cancer with radiation. The product is approved in Europe and will be further developed for future market introduction in the US.
Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California and Dallas, Texas. Learn more at palettelifesciences.com and pharmanest.se.
Deflux®, Solesta®, Barrigel®, Restylane®, and NASHA™ are registered trademarks.
*In the US, this product is considered investigational and not available for commercial sale in the US.
Location: Sweden, Stockholm
Employees: 51-200
Total raised: $40M
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | Warren Poi... | warrenpoin... |
| 30.08.2023 | OrbiMed | orbimed.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.10.2021 | - | $40M | - |
Mentions in press and media 21
| Date | Title | Description |
| 30.05.2023 | Palette Life Sciences Welcomes New Barrigel® Center of Excellence Program Designations | /EIN News/ -- Recognizing exceptional leadership in patient education and clinical skill in the Barrigel procedure SANTA BARBARA, Calif. and STOCKHOLM, Sweden, May 30, 2023 (GLOBE NEWSWIRE) -- Palette Life Sciences, a fully-integrated globa... |
| 09.02.2023 | Palette Life Sciences Announces Publication of Barrigel® Pivotal Safety and Efficacy Clinical Trial Data in JAMA Oncology | Rectal spacing with Barrigel® is proven safe and effective in improving rectal dosimetry and reducing acute Grade 2+ GI toxicity in first FDA-reviewed randomized controlled trial of rectal spacing using hypofractionated radiotherapy /EIN Ne... |
| 09.02.2023 | Palette Life Sciences tillkännager publicering av Barrigel® Säkerhets- och effektdata i JAMA Oncology | Den pivotala studien visar att separation av rektum och prostatan med Barrigel® är säkert och effektivt när det gäller att förbättra rektal dosimetri och minska akut toxicitet av grad 2+. Studien är den första FDA-granskade, randomiserade, ... |
| 09.06.2022 | Palette Life Sciences tillkännager FDA godkännande av Barrigel®, en produkt som minimera skadliga och långvariga biverkningar från strålbehandling av prostatacancer | Banbrytande teknologi minskar risken för strålskador i ändtarmen – bättre kontroll och optimerad lokalisering av stråldosen SANTA BARBARA, Calif. och STOCKHOLM, Sverige, June 09, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences, ett globalt m... |
| 09.06.2022 | Palette Life Sciences Announces FDA 510(k) Clearance for Barrigel® Rectal Spacer, Proven Safe and Effective at Minimizing the Harmful Long-Term Side Effects of Prostate Radiation Therapy | SANTA BARBARA, Calif. and STOCKHOLM, Sweden, June 09, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences, a fully-integrated global life sciences company dedicated to improving patient outcomes, today announced U.S. Food and Drug Administration... |
| 29.03.2022 | Palette Life Sciences Receives Favorable Post Approval Study Results for Solesta® | SANTA BARBARA, Calif. and STOCKHOLM, Sweden, March 29, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced the results of their Solesta® Po... |
| 24.02.2022 | Palette Life Sciences inleder ett samarbete med Lantheus för att marknadsföra PYLARIFY® (piflufolastat F-18) | SANTA BARBARA, Calif. och STOCKHOLM, Sverige, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences (”Palette”), ett globalt företag inom medicinteknik som arbetar för att förbättra behandlingsresultaten av bland annat strålbehandling av ... |
| 24.02.2022 | Palette Life Sciences Enters Into an Agreement with Lantheus to Support the Promotion of PYLARIFY® (Piflufolastat F18) | Partnership leverages Palette’s specialty sales team to increase promotional footprint of PYLARIFY within the urology call point SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences (“Palette”... |
| 15.02.2022 | Palette Life Sciences Announces the Establishment of a Wholly Owned Subsidiary in Japan | Expansion will allow for Palette Life Sciences to provide better support to healthcare providers in Japanese market SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences, a fully integrated glo... |
| 15.02.2022 | Palette Life Sciences tillkännager bildandet av ett helägt dotterbolag i Japan | Utvidgningen kommer att göra det möjligt för Palette Life Sciences att ge bättre stöd till vårdgivare på den japanska marknaden SANTA BARBARA, Kalifornien och STOCKHOLM, Sverige, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences, ett ... |
Show more